Institution
Inova Health System
Healthcare•Falls Church, Virginia, United States•
About: Inova Health System is a healthcare organization based out in Falls Church, Virginia, United States. It is known for research contribution in the topics: Population & Fatty liver. The organization has 553 authors who have published 772 publications receiving 33820 citations. The organization is also known as: Fairfax Hospital Association.
Topics: Population, Fatty liver, Nonalcoholic fatty liver disease, Chronic liver disease, Hepatitis C
Papers published on a yearly basis
Papers
More filters
TL;DR: As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous, and random‐effects models were used to provide point estimates of prevalence, incidence, mortality and incidence rate ratios.
6,746 citations
TL;DR: Aliment Pharmacol Ther 2011; 34: 274–285
Abstract: SUMMARY Background Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, and its worldwide prevalence continues to increase with the growing obesity epidemic. This study assesses the epidemiology of NAFLD in adults based on clinical literature published over the past 30 years. Aim To review epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults based on clinical literature published over the past 30 years. Methods An in-depth search of PubMed (1980–2010) was based on five search terms: ‘nonalcoholic fatty liver disease’ OR ‘non-alcoholic steatohepatitis’ OR ‘fatty liver’ OR ‘steatosis’ AND ‘incidence’ [MeSH Terms] OR ‘prevalence’ [MeSH Terms] OR ‘natural history’. Studies of paediatric cohorts were excluded. Articles were categorised by topic and summarised, noting generalisations concerning their content.
2,679 citations
TL;DR: Patients with NASH are less likely to undergo liver transplantation (LT) andLess likely to survive for 90 days on the waitlist than patients with HCV, ALD, or HCV and ALD.
1,444 citations
TL;DR: Given the rapidly growing global burden of NAFLD and NASH, efforts must continue to find accurate non-invasive diagnostic and prognostic biomarkers, to develop effective treatments for individuals with advanced NASH and prevention methods for individuals at high risk of NA FLD and progressive liver disease.
1,173 citations
TL;DR: Evidence is provided supporting high prevalence of NAFLD and NASH in patients with T2DM around the world and regional and global mean prevalence weighted by population size in each country were estimated and pooled using random-effects meta-analysis.
1,032 citations
Authors
Showing all 565 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Lance A. Liotta | 153 | 832 | 102335 |
| Zobair M. Younossi | 106 | 759 | 62073 |
| Emanuel F. Petricoin | 93 | 488 | 36145 |
| Zachary Goodman | 86 | 302 | 41964 |
| Thomas P. Conrads | 68 | 202 | 18375 |
| Alex H. Krist | 60 | 203 | 13262 |
| Mark N. Hadley | 59 | 182 | 12219 |
| Jeffrey J. Olson | 58 | 310 | 21159 |
| Lynn H. Gerber | 56 | 214 | 11459 |
| Joan H. Schiller | 50 | 203 | 10321 |
| Maria Stepanova | 48 | 220 | 9559 |
| Beverly C. Walters | 47 | 169 | 7529 |
| Linda Henry | 42 | 197 | 12359 |
| Kathleen M. Darcy | 39 | 97 | 4522 |
| Benjamin D. Solomon | 39 | 143 | 5189 |